TABLE 2

QTL with the highest LOD score in any single scan

Chromosome (bp)LODaIntervalb (kb)DrugCrossP(QTL × CYS4)Cross-specificd
2 (413,404)5.1367–4601MY-SY0.46
4 (512,797)6.9482–5203All except MYc0.074Yes (MY, MS, YS)
4 (1,170,947)5.51140–122429MY3.8 × 10−6*NA
5 (265,654)4.2219–3104MS0.23NA
7 (886,487)4.8838–9292MY0.021Yes (MY)
8 (33,410)4.81–8121MY0.0014*NA
8 (479,987)4.9448–5141MY–MS0.52
12 (461,183)5.6406–50019MY–MS0.0059
13 (317,754)5.3287–5464MY–MS0.055
14 (451,294)5.1407–47610, 16MY, MY–MS, MY–YS4.1 × 10−7*No (MY, YS)
14 (531,242)3.9429–56912, 22YSc, MY–YS, MS–YS0.11Yes (YS)
15 (181,894)6.5121–19431MY–MS0.013
15 (381,869)4.9322–43112MY0.022NA
15 (642,515)4.7588–67923MY–YS0.60
16 (382,638)4.5363–4185, 15, 22, 24, 26MY0.00011*NA
16 (894,088)6.3860–92227MY, MY–YS0.32No (MY, YS)
  • *The significance of including an interaction term between the QTL and CYS4 after Bonferroni correction is <0.05.

  • a The maximum LOD for each unique QTL.

  • b The intersection of pleiotropic QTL intervals defined by a 1.5-drop in LOD score, preferably from an individual cross.

  • c QTL identified without covariate; all others were identified using CYS4 as a covariate.

  • d The cross in parentheses indicates in which cross a QTL showed cross-specific effects. NA indicates that the test was not applicable since cross-specific effects were not detected in either of the two combined cross analyses.